Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Phase 2

Completed

Conditions: Hepatitis C
Pharmacokinetics

Interventions: Drug: pegylated interferon (PegIFN) alfa-2a
Drug: Placebo
Drug: BI 201335 NA low placebo
Drug: ribavirin (RBV)
Drug: BI 201335 NA high
Drug: BI 201335 NA low
Drug: BI 201335 NA high placebo

First Posted Date: 2009-07-28

Last Posted Date: 2015-07-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 22

Registration Number: NCT00947349

Locations: 🇯🇵
1220.14.003 Boehringer Ingelheim Investigational Site, Kurashiki, Okayama, Japan
🇯🇵
1220.14.002 Boehringer Ingelheim Investigational Site, Nishinomiya, Hyogo, Japan
🇯🇵
1220.14.001 Boehringer Ingelheim Investigational Site, Minato-ku, Tokyo, Japan

Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise

Completed

Conditions: Hypertension

First Posted Date: 2009-07-27

Last Posted Date: 2019-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18299

Registration Number: NCT00946829

Locations: 🇾🇪
Boehringer Ingelheim Investigational Site, Boehringer Ingelheim Investigational Site, Yemen

PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg

Completed

Conditions: Hypertension

First Posted Date: 2009-07-09

Last Posted Date: 2014-04-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3184

Registration Number: NCT00936208

Locations: 🇪🇬
Boehringer Ingelheim Investigational Site 16, Alexandria West, Egypt
🇪🇬
Boehringer Ingelheim Investigational Site 21, Alexandria, Egypt
🇪🇬
Boehringer Ingelheim Investigational Site 12, Cairo, Egypt

and more 117 locations

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: linagliptin QD (once daily) for 7 days

First Posted Date: 2009-07-08

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 41

Registration Number: NCT00935220

Locations: 🇺🇸
1218.55.0004 Boehringer Ingelheim Investigational Site, Miami, Florida, United States
🇺🇸
1218.55.0008 Boehringer Ingelheim Investigational Site, Deland, Florida, United States
🇺🇸
1218.55.0006 Boehringer Ingelheim Investigational Site, Cypress, California, United States

and more 3 locations

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

Conditions: HIV Infections

First Posted Date: 2009-07-07

Last Posted Date: 2016-11-30

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT00933205

Locations: 🇧🇪
1182.16.3202 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium
🇧🇪
1182.16.3203 Boehringer Ingelheim Investigational Site, Brussel, Belgium
🇧🇪
1182.16.3204 Boehringer Ingelheim Investigational Site, Gent, Belgium

and more 212 locations

(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis

Phase 2

Completed

Conditions: Abdominal Pain

Interventions: Drug: Placebo
Drug: HBB 20 mg

First Posted Date: 2009-07-03

Last Posted Date: 2022-05-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 197

Registration Number: NCT00932737

Locations: 🇺🇸
202.839.01003 Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States
🇺🇸
202.839.01005 Boehringer Ingelheim Investigational Site, Indianapolis, Indiana, United States
🇺🇸
202.839.01009 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States

and more 16 locations

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: BI 1744 (Olodaterol) Medium Dose
Drug: BI 1744 (Olodaterol) Low Dose
Drug: Foradil

First Posted Date: 2009-07-03

Last Posted Date: 2016-02-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 100

Registration Number: NCT00932646

Locations: 🇺🇸
1222.25.25009 Boehringer Ingelheim Investigational Site, Jasper, Alabama, United States
🇺🇸
1222.25.25010 Boehringer Ingelheim Investigational Site, Austell, Georgia, United States
🇺🇸
1222.25.25008 Boehringer Ingelheim Investigational Site, Albuquerque, New Mexico, United States

and more 10 locations

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Foradil
Drug: bi1744
Drug: BI 1744
Drug: Placebo

First Posted Date: 2009-07-02

Last Posted Date: 2014-07-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 99

Registration Number: NCT00931385

Locations: 🇺🇸
1222.24.24009 Boehringer Ingelheim Investigational Site, Overland Park, Kansas, United States
🇺🇸
1222.24.24002 Boehringer Ingelheim Investigational Site, Cincinnati, Ohio, United States
🇺🇸
1222.24.24010 Boehringer Ingelheim Investigational Site, Oklahoma City, Oklahoma, United States

and more 8 locations

Actuation Indicator Trial in Patients With COPD

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Device: Ipratropium bromide

First Posted Date: 2009-06-26

Last Posted Date: 2014-07-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 142

Registration Number: NCT00928746

Locations: 🇺🇸
244.2507.0103 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
🇺🇸
244.2507.0104 Boehringer Ingelheim Investigational Site, Greenville, South Carolina, United States
🇺🇸
244.2507.0101 Boehringer Ingelheim Investigational Site, Union, South Carolina, United States

and more 4 locations

Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Olodaterol (BI1744CL)
Drug: Placebo

First Posted Date: 2009-06-26

Last Posted Date: 2014-07-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT00928668

Locations: 🇨🇦
1222.4.103 UBC - Respiratory Medicine, Vancouver, British Columbia, Canada
🇨🇦
1222.4.102, Saskatoon, Saskatchewan, Canada
🇨🇦
1222.4.104 Department of Medicine, Health Sciences Centre, Hamilton, Ontario, Canada

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy